Green AntibioticsLaboratory evidence
Next gate Patent filing, characterisation, safety work and controlled in-vivo evidence.
Science-led venture building
We build science into investable programmes.
AVIX Pharmaceuticals Limited builds and advances science-led ventures across immune health, animal health and functional hydration—taking each programme only as far as the evidence supports.
AVIX PLATFORM3×VENTURE ENGINES
Human immune health
Green AntibioticsAnimal health & AMR
AVIX WaterFunctional hydration
3Science-led ventures
260Adults in T-Booster studies
£700K+Invested in T-Booster to date
2 countriesUK + Bangladesh operations
The AVIX portfolio
Different markets.One venture-building method.
Human immune health, animal-health antimicrobial resistance and functional hydration need different evidence, partners and routes to market. AVIX links them through one operating logic: define the problem, build the solution, generate the next proof and advance only when the data justify it.
Human immune health
t-booster.co.uk ↗
T-Booster
An 18-ingredient nutritional formulation designed around thymus support and healthy immune ageing. Two controlled human studies are complete; interpretation, IP and launch preparation continue.
260Adults
studied
studied
66,000UK GMP
capsules
capsules
4 yrsResearch &
development
development
Animal health & AMR
greenantibiotics.co.uk ↗
Green Antibiotics
A defined plant-derived antimicrobial discovery programme for poultry and aquaculture. Forty-one combinations have been screened, seven leads selected and the current evidence remains in-vitro.
41Combinations
screened
screened
7Leads
selected
selected
LabEvidence
stage
stage
Functional hydration
avixwater.co.uk ↗
AVIX Water
A hydration platform built on controlled purification, defined formulations and one shared quality architecture. Four finished products now sit on one operational base ready for production transfer.
4Finished
products
products
1Shared
platform
platform
BD → GCCMarket
pathway
pathway
Portfolio position
Three ventures.Three different stages.
A single-asset company rises and falls on one gate. AVIX is staggered by design: one venture is preparing for market, one is preparing for its first plant, and one is a reproducible laboratory proof. The important point is to show exactly where each venture sits and what the next proof step is.
Venture
01 · Define
02 · Specify
03 · Laboratory proof
04 · Controlled study
05 · Manufacturing route
06 · Market entry
Green AntibioticsLaboratory evidence
Next gatePatent filing, characterisation, safety work and controlled in-vivo evidence.
AVIX WaterManufacturing route
Next gateQualified production, plant commissioning and measured first-market demand.
T-BoosterLaunch preparation
Next gateFinal interpretation, publication/IP and disciplined commercial execution.
- 01DefineProblem and need
- 02SpecifySolution and protocol
- 03Laboratory proofReproducible evidence
- 04Controlled studyStructured validation
- 05Manufacturing routeQualified productionAVIX WaterManufacturing route
Next gate Qualified production, plant commissioning and measured first-market demand.
- 06Market entryLaunch and commercial proofT-BoosterLaunch preparation
Next gate Final interpretation, publication/IP and disciplined commercial execution.
Stage positions describe development progress, not forecasts of approval, launch, valuation or return. Green Antibiotics remains in-vitro; T-Booster is a supplement programme; AVIX Water products are foods and beverages rather than medicines.
The AVIX method
The markets differ.The sequence does not.
Human supplements, animal-health antimicrobials and drinking water do not share one regulator, one channel or one customer. What they do share is the order of work—and the discipline to stop at any stage the evidence does not support.
Choose the problem
Start with the need.Frame a measurable problem.Challenge it, then solve it.
Specify the solution
Turn rationale into a solution.Define what will be tested.Make assumptions measurable.
Generate evidence
Use the right comparator.Measure what matters most.Keep uncertainty visible.
Create the pathway
Connect evidence to market.Prepare IP, production, partners.Advance when data support it.
One method · three expressions
One method.Three expressions.
The same sequence appears in three very different forms: a clinically studied immune-health product, a plant-derived animal-health discovery programme and a hydration platform built for operational scale.
Biology↓formulation↓human research
AVIX translated immune-ageing rationale into a defined formula, manufactured it under UK GMP and completed controlled human studies before preparing a launch pathway.
Screening↓lead selection↓validation plan
Literature-guided selection, systematic screening and defined three-compound cocktails narrowed 41 combinations to seven leads, ready for the next validation gate.
Specification↓verification↓production transfer
Water treatment, formulation, packaging and release were gathered into one operational platform so four products can move into qualified manufacturing.
The ventures in detail
What each venture has built.What comes next.
The same AVIX method produces three very different programmes. Each chapter below uses the same simple structure: what has been built, the four numbers that matter, what the evidence means, and the next value gate.
Venture 01 · Human immune health
T-Booster: immune ageing.Taken through human research.
The thymus helps develop precursor cells into specialised T cells and its activity declines with age. T-Booster is an 18-ingredient food supplement developed around that biology—and it is the AVIX programme that has travelled furthest towards market.
T-Booster
18Selected ingredients
260Adults across two controlled studies
66,000Capsules produced under UK GMP
£700K+Invested in the programme to date
01
Why the thymus matters
The thymus helps developing T cells mature and supports the supply of newly formed T cells. Its activity naturally declines with age, making healthy immune ageing a meaningful biological challenge.
02
Why AVIX created T-Booster
AVIX translated that age-related biology into an 18-ingredient nutritional formulation, selecting ingredients and doses around thymus support rather than building a general multivitamin.
03
How T-Booster is designed to help
The formulation brings complementary vitamins, minerals and nutraceuticals together around one defined purpose: supporting thymus function and healthy immune ageing.
04
We took the idea into human research
The programme moved from formulation into UK GMP manufacture and controlled human research involving 260 adults, supported by a 66,000-capsule production batch.
05
What makes the evidence interesting
The programme looks at the story from several directions: participant-reported outcomes, TREC DNA as a marker associated with newly generated T cells and thymic output, and wider blood and lymphocyte measures. Final analysis and interpretation continue.
Venture 02 · Animal health & AMR
Green Antibiotics: defined combinations.Measured in the laboratory.
Green Antibiotics does not rely on an undefined herbal blend. It systematically screens defined plant-derived combinations against resistant bacteria, selects the leads that reproduce, and stops the combinations that do not.
41Defined combinations screened
7Lead combinations advanced
34Combinations stopped and recorded
3Complementary compounds in every lead
01
A global AMR crisis
Bacterial AMR is projected to cause 39 million directly attributable deaths from 2025–2050, with potential annual global GDP losses reaching US$1.7 trillion by 2050—making this both a health and economic emergency.
02
Animal agriculture is part of it
Antibiotic use in livestock can select resistant bacteria that move through animals, people, food, water and the environment. Practical animal-health alternatives are therefore part of the wider One Health response.
03
A defined combination strategy
AVIX screens defined plant-derived compounds in deliberate combinations rather than using an undefined herbal mixture. Forty-one combinations were tested and seven reproducible leads advanced.
04
Promising evidence, next proof ahead
The strongest three-compound blend produced 15 mm inhibition against MRSA and 20 mm against Salmonella Typhi in the reported assay. Patent filing, MIC/MBC, safety and controlled animal work remain next.
AV-01 laboratory series
Clear-zone diameter · mm
Green Antibiotics against resistant bacteria
Larger clear zones indicate stronger bacterial-growth inhibition within this laboratory assay.
MRSASalmonella Typhi
MRSA = methicillin-resistant Staphylococcus aureus.
Values are methicillin-resistant Staphylococcus aureus (MRSA) / Salmonella Typhi. These are in-vitro screening data. They do not establish dose-normalised potency against a different comparator and do not demonstrate safety or efficacy in live animals.
Venture 03 · Mineral & functional hydration
AVIX Water: four products.One controlled platform.
Reverse osmosis can remove contaminants and also strip dissolved minerals. AVIX Water treats purification, finished composition, verification, filling and release as one operating system rather than treating the bottle as the whole product.
4Finished products
one shared system
one shared system
1Quality & production
platform
platform
BDFirst proof
market
market
GCCExpansion
pathway
pathway
01
Safe water is more than purification
Reverse osmosis can remove contaminants, but it can also remove naturally dissolved calcium, magnesium and other minerals. AVIX Water treats the finished composition as part of the product—not an afterthought.
02
The Bangladesh comparison revealed a gap
The cited Bangladesh comparison found very low calcium and magnesium in sampled local bottled waters compared with several other water sources. That made finished mineral design a practical product-development question.
03
AVIX designs the finished bottle
Purification, defined mineral or functional formulation, verification, filling, packaging and release are managed as one controlled platform supporting four finished products.
04
Prove the product, then prove the market
Bangladesh is the first proof market. Qualified manufacturing and measured demand come first, with selective GCC expansion considered only after that operating evidence is built.
Bangladesh water comparison
Mean mineral content · mg/L
Calcium and magnesium in sampled waters
The comparison helps show why AVIX treats finished mineral composition as part of product design rather than assuming all purified water is nutritionally equivalent.
Calcium reference context20–30 mg/L · potentially beneficial level
Magnesium reference context10 mg/L · potentially beneficial level
Local bottled brands23 samples
Calcium2.50 mg/L
Magnesium2.42 mg/L
Tube-well water3 samples
Calcium53.44 mg/L
Magnesium32.06 mg/L
Zamzam samples3 samples
Calcium96.00 mg/L
Magnesium36.00 mg/L
Imported brands2 samples
Calcium120.00 mg/L
Magnesium15.10 mg/L
Source context: Uddin et al., Water 13, 2026 (2021). That paper reports local bottled-water means of 2.5 mg/L calcium and 2.42 mg/L magnesium; tube-well water 53.44/32.06 mg/L; Zamzam 96/36 mg/L; and imported bottled water 120/15.1 mg/L. It also discusses 20–30 mg/L calcium and 10 mg/L magnesium as potentially beneficial benchmark levels, while noting broader country and WHO ranges.
The group platform
Eight disciplines.One shared platform.
AVIX should not claim that the ventures share the same science. What they share is a reusable platform for company building: framing, evidence planning, product definition, manufacturing thinking and commercial translation.The ventures do not share the same science. They share one company-building discipline: framing, evidence, product definition, manufacturing and commercial translation.
Problem framing
Define the biological, consumer orproduction problem precisely enoughto test and challenge.
Scientific design
Turn rationale into a clear hypothesis,formulation logic or selectionprotocol.
Screening & evidence
Choose assays, studies or verificationmatched to the most importantclaim-relevant proof point.
Formulation design
Translate ideas into defined products,combinations and specifications,not vague concepts.
Data interpretation
Separate what the evidence showsfrom what remains uncertain,planned or dependent.
Manufacturing pathway
Connect products to quality systems,release controls, suppliers andscalable production.
IP & partner network
Coordinate advisors, laboratories,manufacturers and IP aroundclearly defined gates.
Commercial translation
Turn bounded evidence into a realisticmarket route without presentingunproven outcomes as achieved.
AVIXGROUP PLATFORM
Leadership
Drug-discovery leadersbehind AVIX.
Dr Md Arif Sheikh leads scientific direction, product translation and venture building across all three AVIX programmes. Dr David Brown contributes more than 50 years of pharmaceutical R&D and drug-discovery experience, with his AVIX advisory involvement focused specifically on T-Booster and Green Antibiotics.
Scientific FounderFounder & CEO · PhD
Dr Md Arif Sheikh
Drug discoverer, cancer scientist & venture builder
Dr Md Arif Sheikh leads the scientific and entrepreneurial direction of AVIX Pharmaceuticals. With more than 20 years across molecular biology, structural biology, cancer research and drug discovery, he translates research into defined products, evidence programmes, IP strategy and commercial pathways across T-Booster, Green Antibiotics and AVIX Water.
20+ yearsDrug discovery
45+ structuresProtein science
3 venturesAVIX portfolio
Drug discoveryStructural biologyVenture buildingProduct translation
Scientific AdvisorScientific Advisor · PhD, FRSM, FRSC
Dr David Brown
Drug discoverer & co-inventor of Viagra
Dr David Brown brings more than 50 years of pharmaceutical research, drug discovery and company leadership. A co-inventor on the Viagra patent and former senior R&D leader across major pharmaceutical organisations, he advises AVIX on scientific evaluation, development strategy and commercial judgement, with particular involvement in T-Booster and Green Antibiotics.
50+ yearsPharmaceutical R&D
ViagraCo-inventor
2,000+Scientists led
Drug discoveryPharmaceutical R&DMedicinal chemistryScientific advisory
Investor overview
Capital mapped.To the next proof point.
The investor story is stronger when the use of capital is attached to a specific technical or commercial gate rather than generic growth language. Each AVIX venture has a distinct next ask and risk profile.
Complete interpretation and prepare the launch.
Translate the developed R&D base into final interpretation, publication/IP work and a compliant launch programme.
- Final analysis and manuscript preparation
- Publication and IP execution
- Manufacturing and distribution preparation
Protect, characterise and test in vivo.
Fund the work that determines whether promising in-vitro leads can become a defensible animal-health product.
- Priority patent filing
- MIC/MBC and safety work
- Controlled poultry evidence
Build the first qualified production asset.
Move verified formulations into controlled production and measure real demand before regional expansion.
- Plant and utilities
- Quality and release capability
- Bangladesh first-market launch
AVIX programmes carry scientific, regulatory, manufacturing and commercial risk. Final study analysis, live-animal evidence, qualified manufacturing or market performance may change the investment case.
01 · GET IN TOUCH
Start a conversation
with the AVIX team.
Use the enquiry form or contact the team directly about investment, licensing, distribution, science, media, careers or general enquiries.